Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079475461> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2079475461 endingPage "93" @default.
- W2079475461 startingPage "93" @default.
- W2079475461 abstract "The recent FDA approval of rituximab, a monoclonal antibody, may herald a change in the outlook for the socalled “low-grade” lymphomas. Monoclonal antibodies had previously been FDA approved for diagnostic purposes (arcitumomab is used for scanning) and for nonneoplastic therapeutic purposes (abciximab is used for prevention of reocclusion after coronary angioplasty). Rituximab, a “humanized” monoclonal antibody, is the first to be approved for the therapy of neoplastic disease after a multicenter trial showed a 48% overall response among 166 patients with relapsed or refractory lowgrade lymphoma (1). These preliminary results suggest that biological agents may provide a way to attack diseases which respond to but are not cured with chemotherapeutic agents alone, such as is the case with the lowgrade lymphomas. The review paper by McLaughlin published in this issue provides the necessary background information for the reader to be aware of the numerous approaches taken to treat the follicular lymphomas (the most common of the low-grade or indolent forms of the disease), but may provide a somewhat overoptimistic prognostic impression by emphasizing “plateaus after 5-7 years” for studies with median follow-up of less than 10 years (as must by force be the case for types of treatment initiated only in the last 5-10 years). This group of diseases, as the author points out, has a median overall survival well over 7 years, and the median duration of response to most firstline therapeutic modalities is usually more than 5 years. Some patients who achieve a negative PCR status for the bcl-2 rearrangement subsequently reverted to a positive state, as pointed out by McLaughlin. We, therefore, caution anyone from using the term “cure” for this group of indolent disorders characterized by excessive survival of the neoplastic cells without necessarily an increase in their proliferation (2)." @default.
- W2079475461 created "2016-06-24" @default.
- W2079475461 creator A5000847240 @default.
- W2079475461 date "1999-01-01" @default.
- W2079475461 modified "2023-09-28" @default.
- W2079475461 title "Low-Grade Lymphomas" @default.
- W2079475461 cites W206701898 @default.
- W2079475461 cites W4233484287 @default.
- W2079475461 doi "https://doi.org/10.1080/07357909909011721" @default.
- W2079475461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10999053" @default.
- W2079475461 hasPublicationYear "1999" @default.
- W2079475461 type Work @default.
- W2079475461 sameAs 2079475461 @default.
- W2079475461 citedByCount "1" @default.
- W2079475461 crossrefType "journal-article" @default.
- W2079475461 hasAuthorship W2079475461A5000847240 @default.
- W2079475461 hasBestOaLocation W20794754611 @default.
- W2079475461 hasConcept C126322002 @default.
- W2079475461 hasConcept C143998085 @default.
- W2079475461 hasConcept C159654299 @default.
- W2079475461 hasConcept C203014093 @default.
- W2079475461 hasConcept C2777058707 @default.
- W2079475461 hasConcept C2779134260 @default.
- W2079475461 hasConcept C2779338263 @default.
- W2079475461 hasConcept C2780653079 @default.
- W2079475461 hasConcept C542903549 @default.
- W2079475461 hasConcept C71924100 @default.
- W2079475461 hasConceptScore W2079475461C126322002 @default.
- W2079475461 hasConceptScore W2079475461C143998085 @default.
- W2079475461 hasConceptScore W2079475461C159654299 @default.
- W2079475461 hasConceptScore W2079475461C203014093 @default.
- W2079475461 hasConceptScore W2079475461C2777058707 @default.
- W2079475461 hasConceptScore W2079475461C2779134260 @default.
- W2079475461 hasConceptScore W2079475461C2779338263 @default.
- W2079475461 hasConceptScore W2079475461C2780653079 @default.
- W2079475461 hasConceptScore W2079475461C542903549 @default.
- W2079475461 hasConceptScore W2079475461C71924100 @default.
- W2079475461 hasIssue "1" @default.
- W2079475461 hasLocation W20794754611 @default.
- W2079475461 hasLocation W20794754612 @default.
- W2079475461 hasOpenAccess W2079475461 @default.
- W2079475461 hasPrimaryLocation W20794754611 @default.
- W2079475461 hasRelatedWork W1489975082 @default.
- W2079475461 hasRelatedWork W1605480625 @default.
- W2079475461 hasRelatedWork W1999292710 @default.
- W2079475461 hasRelatedWork W2029682338 @default.
- W2079475461 hasRelatedWork W2030997814 @default.
- W2079475461 hasRelatedWork W2059098879 @default.
- W2079475461 hasRelatedWork W2077812772 @default.
- W2079475461 hasRelatedWork W2174990671 @default.
- W2079475461 hasRelatedWork W2272066067 @default.
- W2079475461 hasRelatedWork W2336001549 @default.
- W2079475461 hasRelatedWork W2557121801 @default.
- W2079475461 hasRelatedWork W2562327681 @default.
- W2079475461 hasRelatedWork W2594607902 @default.
- W2079475461 hasRelatedWork W2744224321 @default.
- W2079475461 hasRelatedWork W2912558146 @default.
- W2079475461 hasRelatedWork W3107970905 @default.
- W2079475461 hasRelatedWork W3200566808 @default.
- W2079475461 hasRelatedWork W3211175389 @default.
- W2079475461 hasRelatedWork W68369743 @default.
- W2079475461 hasRelatedWork W2138053896 @default.
- W2079475461 hasVolume "17" @default.
- W2079475461 isParatext "false" @default.
- W2079475461 isRetracted "false" @default.
- W2079475461 magId "2079475461" @default.
- W2079475461 workType "article" @default.